Jubilant Biosys entered into a research collaboration agreement with AstraZeneca that is focused on delivering drug candidates into AstraZeneca's preclinical pipeline. Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca.